Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-s ...

Today, Seraphina Therapeutics, the pioneer in healthspan-extending nutrient research, announced an addition to its leadership ...

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25. If approved, FILSPARI could be the first and only approv ...

Diane Simeone, MD, credits her fascination with human biology and dedication as a student athlete with instilling in her a ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical ...

Learn more about the event at www.virtualinvestorconferences.com.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 ...

"Everything injected into the bloodstream is eventually ends up in the liver — that's just how our anatomy works," Professor ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...